Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Greco, F. A.
Infante, J. R.
Burris, H. A.
Jones, S. F.
Kolesar, J.
Gardner, L. R.
Sportelli, P.
Bendell, J. C.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[4] Keryx Biopharmaceut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14086
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Ervin, Thomas J.
    Senzer, Neil N.
    Richards, Donald A.
    Firdaus, Irfan
    Lockhart, A. Craig
    Cohn, Allen Lee
    Saleh, Mansoor N.
    Gardner, Lesa R.
    Sportelli, Peter
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).
    Richards, D. A.
    Nemunaitis, J. J.
    Vukelja, S. J.
    Hagenstad, C. T.
    Campos, L. T.
    Letzer, J. P.
    Hermann, R. C.
    Sportelli, P.
    Gardner, L. R.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Final results of a pharmacokinetic (PK) study of capecitabine (X) in combination with oxaliplatin (0) for patients (pts) with metastatic colorectal cancer (MCRC).
    Gil-Delgad, M
    Bastian, G
    Paule, B
    Spano, JP
    Rixe, O
    Guetz, GD
    Urien, S
    Amaury-Soares, J
    Breau, JL
    Castaing, D
    Khayat, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 292S - 292S
  • [4] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
  • [5] Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)
    Adamo, Vincenzo
    Festa, Vincenzo
    Restuccia, Eleonora
    Chiofalo, Giuseppe
    Maisano, Carmelo
    Picciotto, Maria
    Alafaci, Elisabetta
    Tortora, Giampaolo
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 17
  • [6] Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J., Jr.
    Kotasek, D.
    Goldstein, D.
    Tebbutt, N.
    McGreivy, J.
    Sun, Y.
    Yang, L.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK)
    Schreiber, V.
    Kitzmueller, M.
    Buchner, P.
    Weissenboeck, N.
    Lichtneckert, M.
    Greil, R.
    Geiler, H.
    Czejka, M.
    Dittrich, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S361 - S361
  • [8] SUBSET ANALYSIS OF 5-FU REFRACTORY PATIENTS FROM A RANDOMIZED PH II STUDY OF PERIFOSINE plus CAPECITABINE (P-CAP) VS. PLACEBO plus CAPECITABINE (CAP) IN PATIENTS WITH 2ND OR 3RD LINE METASTATIC CRC
    Hoff, P.
    Richards, D.
    Nemunaitis, J.
    Vukelja, S.
    Hagenstad, C.
    Campos, L.
    Letzer, J.
    Sportelli, P.
    Gardner, L.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 16 - 16
  • [9] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [10] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
12345